Market Place
Sourcing Support
All News #Library
Biotech
Q32 Bio Set to Join Needham Healthcare Conference
08 Apr 2026 //
PR NEWSWIRE
Q32 Bio To Join Oppenheimer Healthcare Life Sciences Conference
18 Feb 2026 //
PR NEWSWIRE
Q32 Bio Announces Q3 2025 Financial Results And Corporate Update
13 Nov 2025 //
PR NEWSWIRE
Q32 Bio Completes Enrollment In SIGNAL-AA Phase 2A Trial
21 Oct 2025 //
PR NEWSWIRE
Q32 Bio to Attend 2025 Wells Fargo Healthcare Conference
28 Aug 2025 //
PR NEWSWIRE
Q32 Bio Reports Q2 2025 Financials and Updates on Corporate
07 Aug 2025 //
PR NEWSWIRE
Q32 doses patients in SIGNAL-AA Phase 2a trial for alopecia Areata
16 Apr 2025 //
PR NEWSWIRE
Q32 Bio Reports Q4 2024 Results and Corporate Update
11 Mar 2025 //
PR NEWSWIRE
Q32 Bio’s SIGNAL-AA Data On Bempikibart In Alopecia Areata
08 Mar 2025 //
PR NEWSWIRE
Q32 Bio Restructures to Focus on Bempikibart for Alopecia Areata
10 Feb 2025 //
PR NEWSWIRE
Q32`s stock plunges in wake of anti-IL-7R antibody`s eczema fail
11 Dec 2024 //
FIERCE BIOTECH
Q32 Bio Advances Bempikibart For Alopecia Areata
10 Dec 2024 //
PR NEWSWIRE
Q32 Bio to Participate in Guggenheim`s Inaugural Health Conference
05 Nov 2024 //
PR NEWSWIRE
Q32 Bio To Present ADX-097 Phase 1 Results At ASN Kidney Week
14 Oct 2024 //
PR NEWSWIRE
Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen
16 Nov 2023 //
PR NEWSWIRE
Q32 and Horizon Announce Dosing of First Patient in Phase 2 Trial of Bempikibart
13 Sep 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.